- Home
- WDFC vs AKRO Comparison
WDFC vs AKRO Comparison
Compare WDFC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDFC
- AKRO
- Stock Information
- Founded
- WDFC 1953
- AKRO 2017
- Country
- WDFC United States
- AKRO United States
- Employees
- WDFC N/A
- AKRO N/A
- Industry
- WDFC Major Chemicals
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- WDFC Industrials
- AKRO Health Care
- Exchange
- WDFC Nasdaq
- AKRO Nasdaq
- Market Cap
- WDFC 3.1B
- AKRO 2.8B
- IPO Year
- WDFC N/A
- AKRO 2019
- Fundamental
- Price
- WDFC $222.76
- AKRO $37.63
- Analyst Decision
- WDFC Buy
- AKRO Strong Buy
- Analyst Count
- WDFC 2
- AKRO 9
- Target Price
- WDFC $301.00
- AKRO $76.29
- AVG Volume (30 Days)
- WDFC 172.2K
- AKRO 1.3M
- Earning Date
- WDFC 04-08-2025
- AKRO 05-09-2025
- Dividend Yield
- WDFC 1.69%
- AKRO N/A
- EPS Growth
- WDFC 24.89
- AKRO N/A
- EPS
- WDFC 6.27
- AKRO N/A
- Revenue
- WDFC $610,635,000.00
- AKRO N/A
- Revenue This Year
- WDFC $8.31
- AKRO N/A
- Revenue Next Year
- WDFC $4.71
- AKRO N/A
- P/E Ratio
- WDFC $35.53
- AKRO N/A
- Revenue Growth
- WDFC 8.71
- AKRO N/A
- 52 Week Low
- WDFC $208.00
- AKRO $17.86
- 52 Week High
- WDFC $292.36
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- WDFC 40.55
- AKRO 43.61
- Support Level
- WDFC $215.60
- AKRO $36.46
- Resistance Level
- WDFC $226.16
- AKRO $39.13
- Average True Range (ATR)
- WDFC 10.08
- AKRO 3.04
- MACD
- WDFC -1.78
- AKRO 0.06
- Stochastic Oscillator
- WDFC 32.45
- AKRO 57.38
About WDFC WD-40 Company
WD-40 Co manufactures and sells lubricants and cleaning products. The firm's product categories include maintenance and cleaning products. Maintenance products include the WD-40 signature brand aerosol spray lubricant as well as degreasers, rust removers, and bicycle maintenance products. Cleaning products include toilet cleaners, carpet stain removers and deodorizers, and heavy-duty hand soaps used to clean grease. The company organizes itself into three segments based on geography: Americas, Europe/Middle East/Africa, and Asia-Pacific. The majority of the company's revenue comes from the Americas segment, which includes the United States, Canada, and Latin America.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.